Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis "AbbVie's first-quarter results were well ahead of our ...

Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here’s what investors should know. AbbVie beat analysts’ revenue expectations by 1.9% last ...

It beat convincingly on both the top and bottom lines. For its first quarter of this year, AbbVie's net revenue was $13.3 billion, representing a sturdy 8% improvement on a year-over-year basis.

AbbVie is hoping to extend its range of neurotoxin-based pharma and cosmetic products with trenibotulinumtoxinE (TrenibotE), a short-acting successor to its blockbuster Botox brand, that has just ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of AbbVie (ABBV) with an Overweight rating and $210 price target AbbVie offers a “compelling mix of growth and defense” with a ...

AbbVie Inc.'s Q1 earnings show an 8.4% revenue increase, driven by strong performance in immunology, neuroscience, and oncology divisions, with Skyrizi and Rinvoq leading growth. Despite Humira's ...

AbbVie (NYSE:ABBV) is set to report its first-quarter 2025 earnings on Friday, April 25, ahead of the market open. Wall Street analysts are expecting solid, if moderate, year-over-year growth from ...

AbbVie's Q1 EPS of $2.46 beat estimates; sales rose 8.4% to $13.34 billion, topping consensus of $12.92 billion. Skyrizi and Rinvoq sales surged 70.5% and 57.2%, while Humira dropped 50.6%. Feel ...

It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to ...

AbbVie (ABBV) announced submission of a Biologics License Application to the U.S.FDA for trenibotulinumtoxinE for the treatment of moderate to severe glabellar lines. Discover outperforming stocks ...